Kynmobi (apomorphine hydrochloride), an under-the-tongue therapy approved to help manage off episodes in Parkinson’s disease, is being discontinued in the U.S. as of June 30. Sunovion, which developed the treatment, is voluntarily withdrawing the drug from the U.S. market “due to limited utilization,” according to an announcement…
Kyowa Kirin has discontinued the clinical development of its investigational treatment, KW-6356, for Parkinson’s disease, despite Phase 2 clinical trial data showing promising results as a monotherapy or in combination with levodopa. The decision was based on the “global regulatory landscape, development hurdles, and timelines for potential market…
Due to negative clinical trial findings, Biogen has discontinued the development of cinpanemab (BIIB054), an investigational medication intended to treat Parkinson’s disease, the company announced in its 2020 investors report. Cinpanemab is a human-derived antibody that targets alpha-synuclein, thought to be one of the key hallmarks of Parkinson’s disease. In the…
Teva has discontinued Spiroco (ropinirole) 4mg XL prolonged-release tablets due to factors out of the company’s control, according to an announcement from Parkinson’s UK. The company — which outside the U.S. manufactures ropinirole XL as a generic formulation in three concentrations — is still marketing Spiroco…
Get regular updates to your inbox.
